L&K BioMed's 'BluEx-TM' Receives FDA Approval in the U.S.

L&K BioMed, a company specializing in spinal implants, announced on July 9 that its 'BluEx-TM' product has received approval from the U.S. Food and Drug Administration (FDA), marking the official launch of a new nationwide distribution strategy in the United States.

L&K BioMed submitted its FDA application in June and received final approval on July 8 (local U.S. time). A company representative stated, "This FDA approval goes beyond simple product certification; it is part of a broader effort to completely overhaul our market access strategy, moving away from our previous distribution methods."

BluEx-TM is a new version of the company's PathLoc-TM product, featuring the blue series surface treatment technology. BluEx-TM was developed as a differentiated product line under the same technological foundation as existing products, tailored to the characteristics of each sales channel and distribution network. Through this approach, the company has established a new customized supply system for each distributor.

A company official commented, "The FDA approval was not merely for export purposes, but was a key preparatory step for structurally expanding our distribution network within the United States. Through this approval, we aim to further strengthen the trust of both domestic and international partners and customers."

The official added, "Ahead of our full-scale entry into the U.S. market, we have proactively established a foundation for co-marketing strategy discussions with global distribution partners in the United States."

With BluEx-TM, L&K BioMed has established a flexible contracting and supply system with regional distributors, hospitals, and supply partners. The company expects this will enable competitive product supply and rapid response to market demands.

In addition to the United States, the company is also diversifying its distribution channel strategies in major markets such as Asia and Latin America. L&K BioMed plans to further strengthen its position in the global medical device market through brand differentiation and certification-based customized sales strategies.